These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26859937)

  • 1. [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].
    Mikhaylenko DS; Perepechin DV; Grigoryeva MV; Zhinzhilo TA; Safronova NY; Efremov GD; Sivkov AV
    Urologiia; 2015; (5):46-50. PubMed ID: 26859937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
    Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.
    Väänänen RM; Lilja H; Kauko L; Helo P; Kekki H; Cronin AM; Vickers AJ; Nurmi M; Alanen K; Bjartell A; Pettersson K
    Urology; 2014 Feb; 83(2):511.e1-7. PubMed ID: 24468524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics.
    Mytsyk Y; Nakonechnyi Y; Dosenko V; Kowal P; Pietrus M; Gazdikova K; Labudova M; Caprnda M; Prosecky R; Dragasek J; Kruzliak P; Dats R
    Clin Biochem; 2023 Jun; 116():120-127. PubMed ID: 37121562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia.
    Velaeti S; Dimitriadis E; Kontogianni-Katsarou K; Savvani A; Sdrolia E; Pantazi G; Stefanakis S; Trangas T; Pandis N; Petraki K
    Tumour Biol; 2014 Oct; 35(10):9597-602. PubMed ID: 24961351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological patterns of prostate biopsy in men with fluctuations of prostate cancer gene 3 score: a preliminary report.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Porpiglia F
    Anticancer Res; 2015 Apr; 35(4):2417-22. PubMed ID: 25862908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
    Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers.
    Mengual L; Ars E; Lozano JJ; Burset M; Izquierdo L; Ingelmo-Torres M; Gaya JM; Algaba F; Villavicencio H; Ribal MJ; Alcaraz A
    Actas Urol Esp; 2014 Apr; 38(3):143-9. PubMed ID: 24206626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.